{
    "clinical_study": {
        "@rank": "141284", 
        "arm_group": [
            {
                "arm_group_label": "RO6811135", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will\n      evaluate the efficacy, safety and tolerability of RO6811135 in Type 2 diabetic patients\n      treated with a stable dose of metformin."
        }, 
        "brief_title": "A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults between the age of 18 and 65\n\n          -  Have been diagnosed with diabetes for at least 3 months and treated with a stable\n             dose of metformin for at least 8 weeks\n\n          -  Hemoglobin A1c between 7.2 and 10.5%\n\n          -  Fasting plasma glucose less than 250 mg/dL\n\n          -  C-peptide greater than 1.5 ng/mL\n\n          -  Body mass index (BMI) between 27 and 44\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Type 1 diabetes\n\n          -  Had undergone weight loss surgery or weight loss procedure involving the\n             gastrointestinal tract, such as gastric bypass, gastric stapling, or gastric banding\n\n          -  Uncontrolled hypertension or other significant cardiovascular disease as determined\n             by investigator\n\n          -  Significant kidney or liver disease as determined by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951183", 
            "org_study_id": "NP29013"
        }, 
        "intervention": [
            {
                "arm_group_label": "RO6811135", 
                "description": "Subcutaneously daily", 
                "intervention_name": "RO6811135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "RO681135 placebo subcutaneously daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "2", 
        "official_title": "A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-DAILY RO6811135 IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 12"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951183"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 12"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "19 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Cancelled due to Sponsor's decision"
    }
}